Today's Healthcare Pulse
Abridge teams with Eli Lilly and Nvidia to expand AI scribe platform
Abridge announced a strategic investment from Eli Lilly and a partnership with Nvidia to build a foundation model for clinical conversations. The collaboration aims to broaden Abridge’s AI‑scribe services across more health systems and integrate with payers. The company already supports over 300 health systems.
Also developing:
Louisiana Mayor Alice Wallace Arrested on Six Medicaid Fraud Counts, $75K Illicit Gains
Louisiana Attorney General Liz Murrill announced the arrest of Winnsboro Mayor Alice Wallace on six counts of Medicaid fraud, alleging she illegally secured $75,000 in benefits between 2021 and 2026. The case highlights gaps in eligibility verification and raises questions about oversight of public health funds in small municipalities.
Amazon Launches GLP‑1 Weight‑Loss Program, Targeting $25‑Per‑Month Market
Amazon introduced a GLP‑1 weight‑loss service through its One Medical unit, combining virtual and in‑person care with pharmacy fulfillment, pricing drugs such as Wegovy at $25 per month for insured patients, marking a strategic push into healthcare that could boost...
Dell's Billion-Dollar Gift Positions UT as Health Hub
@MichaelDell is a true leader & visionary. "A society grows old when men plant trees whose shade they'll never sit under." We need more US boomers to step up and reinvest in their grandchildren & communities like Dell. With...
Virus‑Bursting Nanostructured Surfaces Ready After Decade of Research
Scientists have unveiled a virus‑bursting nanomaterial that mimics insect wings, physically rupturing viral particles on contact. The breakthrough, published in Advanced Science after ten years of work, promises an eco‑friendly alternative to chemical disinfectants for healthcare and public‑transport settings.
Lumeris Launches Native Audio for Tom Platform to Address US Primary Care Physician Shortage
Lumeris has launched Native Audio for its Tom primary‑care‑as‑a‑service platform, embedding Google Cloud’s Gemini native‑audio models to enable real‑time speech‑to‑speech interactions. The feature aims to alleviate the U.S. primary‑care crisis, where roughly 100 million adults lack a regular provider and a...
Kelun-Biotech to Unveil Three Oncology Trial Results at 2026 ASCO Meeting
Sichuan Kelun-Biotech Biopharmaceutical announced that it will present results from three clinical studies—sac‑TMT plus pembrolizumab, the RET inhibitor lunbotinib, and the novel ADC SKB500—at the 2026 American Society of Clinical Oncology meeting in Chicago. The disclosures underscore the company's expanding...
Eleos Debuts Agentic AI Suite for Community-Based Care
Eleos launched an agentic AI suite at NatCon 2026, adding Clinical Insights, Revenue Cycle Management, and Compliance tools for community‑based care. The platform embeds a HIPAA‑compliant AI co‑pilot into existing workflows, addressing a "shadow IT" crisis where 57% of providers...
Video Wednesday
On April 22, 2026 the blog posted a short video showcasing the da Vinci SP surgical robot. The clip demonstrates the platform’s single‑port design, 3‑D high‑definition imaging, and articulated instruments that operate through a single incision. The da Vinci SP,...
AI Is Spitting Out More Potential Drugs than Ever. This Start-Up Wants to Figure Out Which Ones Matter.
10x Science, a biotech AI startup founded by former Stanford researchers, announced a $4.8 million seed round led by Initialized Capital. The company’s platform combines deterministic chemistry algorithms with AI agents to automatically interpret mass‑spectrometry data, turning raw spectra into actionable...
The Cost of Implementing and Sustaining the Massachusetts Model
A microcosting study of the Massachusetts Model (MA Model) for office‑based opioid use disorder treatment found average implementation costs of $238,888 per clinic ($3,185 per patient) and annual sustainment costs of $229,676 per clinic ($3,062 per patient). Variable costs, chiefly...
Keebler Health Raises $16M to Advance AI in Healthcare
Keebler Health announced a $16 million Series A round to expand its AI-driven platform for clinical and operational decision‑making. The solution uses machine learning to surface hidden risk patterns, enabling earlier interventions and cost reductions. CEO Isaac Park says the funds will...
AI‑Driven Discoveries Shift Medicine to Understanding the How
The Real Era of the Art of Medicine Begins with Artificial Intelligence. I mean, when AI discovers new treatments and runs in silico clinical trials that physicians, pharma companies, or medical innovators would never think of, our job will be understanding the...
Medical AI Lacks Proof of Patient Care Benefits
On the lack of compelling evidence that medical AI is improving patient care, and what to do about it, a @NatureMedicine editorial https://t.co/kQiN6L2ai7 https://t.co/zhae0bFZ8R
New Review Casts Doubt On Alzheimers Drugs But Is Controversial
A new Cochrane review of 17 trials involving more than 20,000 Alzheimer’s patients concludes that amyloid‑targeting monoclonal antibodies deliver only trivial cognitive benefits and carry safety risks. The analysis groups together all anti‑amyloid antibodies—including older failures—thereby diluting the modest gains...
The Front Office Is Finding Air: One Network’s Early Returns on Operational AI
Capitol Imaging, a multi‑state imaging network, partnered with AbbaDox to roll out modular operational AI, starting with a scheduling assistant and later adding fax‑processing automation. The first 90 days revealed three key realities: undocumented tribal knowledge slowed deployment, a one‑size‑fits‑all...
California Lawmakers Seek Protections for Patients in ICE Custody
California senators introduced two bills to shield patients in ICE custody from isolation and interference at hospitals. SB 915 would largely prohibit "blackout" policies, require notification of families, limit ICE agents in patient rooms, and mandate documentation of officer IDs....
Progress Against Pancreatic Cancer, Part One
Revolution Medicines reported that its RAS‑targeting small molecule daraxonrasib more than doubled overall survival for patients with metastatic pancreatic ductal adenocarcinoma, extending median survival to 13.2 months versus 6.7 months on standard chemotherapy. The drug works by stabilizing a novel...
ADHD, Neurostimulants, and Height Growth Explained
A new Pediatric Research study shows that children with ADHD are slightly shorter than peers, even without medication, after adjusting for genetic height potential. Neurostimulants such as methylphenidate cause only modest, non‑uniform height reductions when genetic baselines are considered. The...
Beyond the Pharmaceutical Model
The post argues that modern medicine is organized around disease classification and long‑term drug management rather than genuine health restoration. It promotes Dr. Sircus’s “terrain theory,” which holds that environmental and lifestyle factors are the true roots of illness. By...
Sweeter Recovery with Reduced IV Fluids in Neonates
A new quality‑improvement protocol for neonatal hypoglycemia, detailed in the Journal of Perinatology, replaces prolonged IV dextrose with a calibrated oral‑feeding regimen and continuous glucose monitoring. The study by Reed, Weintraub and Reinhart shows a statistically significant drop in IV...
Immunotherapy Drug Helps Bladder Cancer Patients Avoid Major Organ Removal
A phase‑2 trial led by NYU Langone Health found that adding pembrolizumab (Keytruda) to standard chemotherapy, radiation, and surgery allowed 60% of patients with muscle‑invasive bladder cancer to avoid cystectomy for up to two years. The study, the largest of...
Lilly, Novo Dip as Proposed Medicare Coverage for GLP-1 Pilot Thrown Off Balance
The Centers for Medicare & Medicaid Services (CMS) has indefinitely postponed its BALANCE financing model, a pilot intended to expand Medicare coverage for GLP‑1 obesity drugs. The delay triggered a roughly 2% drop in Eli Lilly’s share price and a 4%...
Expanding the Toolkit: Non-Statin Therapies, Broader Populations, and Closing the Treatment Gap
The 2026 ACC/AHA guideline now gives strong, Class I recommendations for non‑statin therapies—bempedoic acid, PCSK9 antibodies, ezetimibe and inclisiran—for patients who cannot tolerate statins. It endorses combination regimens, such as a moderate‑intensity statin plus ezetimibe, which the RACING trial showed matches...
INBRAIN Neuroelectronics Completes Patient Recruitment for First-in-Human Study Evaluating Its Graphene Cortical Interface
INBRAIN Neuroelectronics announced that patient recruitment is complete for its first‑in‑human trial of a graphene‑based cortical interface. Ten patients were enrolled, and eight underwent surgery without any peri‑operative device failures, yielding complete datasets. The study, run with the University of...
Eye Practice and Physician Owner Agree to Pay $415,000 to Resolve Allegations of False Claims Act to Medicare
The Mitchell Eye Center and its former owner, Dr. Alan Mitchell, agreed to pay $415,000 to resolve False Claims Act allegations. U.S. authorities say the practice submitted Medicare and Veterans Health Administration claims for transcranial doppler (TCD) tests that were...
11 Key Features to Look for in Medical Practice Management Software for Healthcare Providers
Administrative tasks still consume 15%‑25% of U.S. healthcare spending—about $1 trillion annually—largely due to manual processes. The article outlines 11 essential features of modern medical practice management software that can replace paper charts, spreadsheets, and fax‑based billing with integrated digital workflows....
MSD-Backed Ray Locks in $125m to Back Eye Drug Pipeline
Ray Therapeutics announced a $125 million Series B round, led by Janus Henderson Investors with participation from Merck’s venture arm, MRL Ventures and Novo Holdings. The capital will fund late‑stage clinical work and commercial preparation for RTX‑015, its lead gene‑therapy candidate for...
Immunotherapy Offers Hope in Avoiding Bladder Removal for Cancer Patients
A new immunotherapy regimen combining checkpoint inhibitor pembrolizumab with standard chemoradiation has demonstrated a high rate of bladder preservation in patients with muscle‑invasive bladder cancer. In a multinational Phase III trial of 560 participants, 68% of patients avoided cystectomy at...
Amid US Ordeal, Moderna Wins EU Approval for Flu/COVID-19 Combo Shot
Moderna received European Commission approval for its mCOMBRIAX vaccine, a combined flu and COVID‑19 shot targeting adults 50 and older across all 27 EU members plus Iceland, Liechtenstein and Norway. The combo pairs Moderna’s next‑generation COVID vaccine mNEXSPIKE with the...
An ‘AI Scientist’ Can Tackle Drug R&D. What Does that Mean for Pharma?
AI agents are moving from analytical tools to autonomous coworkers in pharma, with Owkin’s K Pro platform acting as an “AI scientist” that can answer complex research questions in hours rather than weeks. The system pulls together literature, gene‑expression data, and...
New Data Build Case for Roche's Oral BTK Drug for MS
Roche reported that its oral BTK inhibitor fenebrutinib dramatically reduced relapse rates and MRI lesions in two phase 3 FENhance trials for relapsing multiple sclerosis, outperforming Sanofi's Aubagio. The drug cut annualised relapse rates by 51.1% and 58.5% and lowered inflammation...
Epstein-Barr Virus Methylation Aids Nasopharyngeal Cancer Screening
Researchers led by Wu, Z.C. and colleagues introduced an Epstein‑Barr virus (EBV) Cp methylation assay that triages individuals for nasopharyngeal carcinoma (NPC) risk. The method, published in Nature Communications, leverages viral DNA methylation patterns from nasopharyngeal swabs to achieve higher...
Tees, Esk and Wear Talking Therapies Improvement Challenge Highlights Steps to Improve Uptake of Digital
Tees, Esk and Wear Valleys NHS Foundation Trust completed a 100‑day improvement challenge aimed at boosting confidence among adults 65+ in using digital talking‑therapies. Over 240 seniors participated, with 96% reporting regular use of phones, tablets or laptops. Video‑based therapy...
Regeneron Reports P-III (NIMBLE) Trial Data on Cemdisiran for Generalized Myasthenia Gravis (gMG)
Regeneron presented Phase III (NIMBLE) data showing that subcutaneous cemdisiran 600 mg every 12 weeks significantly improved symptoms in adults with generalized myasthenia gravis (gMG) and anti‑AChR antibodies. Over 24 weeks, the cemdisiran arm reduced MG‑ADL scores by 4.5 points versus 2.2...
New Study Reveals CRISPR Enzyme that Responds to Human DNA Methylation
A collaborative team from Wageningen University & Research and the Van Andel Institute has identified a CRISPR-associated enzyme that senses DNA methylation, a key epigenetic mark distinguishing cancer cells from normal tissue. The enzyme selectively binds to methylated human DNA,...
Elevance Health Profits Eclipse $1.7 Billion Despite Elevated Costs
Elevance Health reported first‑quarter net income of $1.76 billion, a 17% decline from a year earlier, while total revenue rose 2.6% to $50.18 billion. The company’s benefit‑expense ratio climbed to 86.8%, reflecting higher medical costs in its Medicaid business despite modest gains...
Merck Steps up as 'Meaningful Competitor' To Gilead with HIV Pill Approval
Merck received FDA approval for Idvynso, a once‑daily, single‑pill regimen for virologically suppressed HIV‑1 adults, slated for U.S. launch on May 11, 2026. The drug demonstrated non‑inferior viral suppression versus continued Biktarvy use in two pivotal trials. Analysts see Idvynso...
Merck to Partner with Google Cloud on AI Initiatives
Merck & Co announced a partnership with Google Cloud to accelerate its artificial‑intelligence capabilities, allocating up to $1 billion over several years. The deal will fund AI infrastructure, licensing of Google’s Gemini Enterprise platform, and dedicated cloud engineers working alongside Merck...
The Deadly Reality of Eclampsia and Maternal Mortality in Nigeria
Eclampsia, a seizure‑inducing progression of pre‑eclampsia, remains a leading cause of maternal death in Nigeria, where maternal mortality exceeds 800 per 100,000 live births. Most affected women are young, first‑time mothers from rural northern communities who receive little or no...
A ‘Barbaric’ Problem in American Hospitals Is Only Getting Bigger
A personal account of a dying husband’s prolonged stays in emergency‑department (ED) boarding highlights a growing crisis in U.S. hospitals. Patients are often kept on stretchers in hallways for 24‑plus hours because inpatient beds are scarce, a problem that has...
WHO Webinar Highlights Health Sector’s Role in Boosting Parental Caregiving
The World Health Organization, together with the Child Health Task Force and the ECD Action Network, is hosting a webinar to examine how health services can embed evidence‑based parenting support from pregnancy through adolescence. Participants will review practical tools and...
FDA Approves MSD’s Once-Daily HIV Combo Idvynso
Merck’s Idvynso (doravirine/islatravir) received FDA approval, marking the first tenofovir‑free, non‑INSTI two‑drug regimen for HIV. The decision follows Phase III trials that demonstrated non‑inferior viral suppression compared with Gilead’s three‑drug standard Biktarvy. Idvynso targets virologically suppressed patients without prior treatment failure...
7 Reasons Traveling For Drug Rehab Improves Treatment Outcomes Nationwide
Traveling for drug rehabilitation acts as an environmental reset that removes patients from familiar triggers, improves detox stabilization, and boosts clinical engagement. Relocating patients enables access to specialized, evidence‑based programs and a highly structured daily routine. The broader perspective gained...
Judge Delays Purdue Pharma Sentencing, Clearing $7 B Settlement Path
U.S. District Judge Madeline Cox Arleo postponed Purdue Pharma's criminal sentencing to allow opioid victims to attend in person. The delay clears the path for a $225 million forfeiture and a $7 billion settlement from the Sackler family, which will fund government...
What to Know About the U.K.’s Generational Smoking Ban
The UK Parliament has approved the Tobacco and Vapes Bill, which will ban the sale of cigarettes, herbal smoking products and cigarette paper to anyone born in 2009 or later, creating a “smoke‑free” generation. The legislation also expands vape‑free zones...
Ipsen’s Ojemda (Tovorafenib) Receives Conditional Approval for R/R BRAF-Altered Pediatric Low-Grade Glioma (pLGG) in the EU
Ipsen’s oral kinase inhibitor Ojemda (tovorafenib) received conditional approval from the European Commission for treating pediatric low‑grade glioma (pLGG) with BRAF fusions, rearrangements or V600 mutations. The indication applies to patients six months or older who have progressed after at...
The UK Passes A Lifetime Smoking Ban. Could America Be Next?
The UK Parliament approved the Tobacco and Vapes Bill, which will permanently bar anyone born on or after Jan. 1, 2009 from purchasing tobacco, with the law taking effect on Jan. 1, 2027. The measure raises the legal smoking age by one year each...
AI Tools Let Surgeons Evaluate Heart Transplants in Minutes, Cutting Wait Times
At the ISHLT 46th Annual Meeting, Dr. Brian Wayda unveiled AI models that let surgeons gauge donor‑heart suitability in minutes. The tools, including the TOPHAT web predictor, could raise the current 30‑40% utilization rate of available hearts and ease the...
CDC Withholds Report Showing Vaccines Reduce Hospitalizations
Can't hide from science. CDC won’t publish report showing covid shots cut likelihood of hospital visits https://t.co/zajDCiaaAJ
Gene Variant, RSV Bronchiolitis Linked to Male Asthma
A new longitudinal study of 3,200 infants found that a common variant in the 17q21 locus dramatically amplifies the risk of developing asthma after early‑life respiratory syncytial virus (RSV) bronchiolitis, but only in male children. Boys carrying the risk allele...